TrialBreast cancer research and treatment2018

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Mothaffar F Rimawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.